ClinicalTrials.gg
CompletedNCT02071589NIFEPAR_PK1Updated Feb 26, 2014

Bioavailability Of A Single Dose Of Nifedipine Oral Solution Compared To Adalat Capsules In Healthy Female Volunteers

A Phase 1 interventional study of Nifedipine soft gelatine capsules and Nifedipine oral solution in Bioequivalence, sponsored by Reig Jofre Group. Completed at 1 site in Spain. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-26.

Sponsored by Reig Jofre Group · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Phase I, crossover, randomised, single dose, relative bioavailability clinical trial of a new oral solution of nifedipine compared to Adalat soft gelatine capsules in healthy female volunteers.

Read the detailed description

The study was designed to compare the bioavailability of nifedipine new formulation specially designed to be used in pre-term labour management instead of anti-hypertensive therapy.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Reig Jofre Group is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 45.
  • Body weight within the normal range (Quetelet index between 19 and 26) expressed as weight (kg) / height (m2) .
  • Medical history , physical examination within normal appliances .
  • No evidence of significant organic or psychiatric disease based on history, physical examination and laboratory tests .
  • Laboratory tests (hematology and biochemistry) within the normal range , according to normal reference values of the Biochemistry laboratory of Hospital de la Santa Creu i Sant Pau. Variations may be allowed based on clinical judgment of the Centre d' Investigacio Medicament (CIM ) .
  • Vital signs: blood pressure (Systolic Blood Pressure (SBP) > 90 \<140 mm Hg / Diastolic Blood Pressure (DBP) > 50 \<90 mm Hg ), heart rate (> 50 \<90 ) , temperature and record within normal range.
  • Not having participated in another clinical trial during the previous three months at the beginning of the current study .
  • Not having donated blood in the previous four weeks.
  • Free acceptance to participate in the trial. Written signed.
  • Use of effective different from oral contraceptives.

Exclusion criteria

Exclusion Criteria:

  • Previous history of alcohol or drug use or abuse during the previous month to the selection process.
  • High consumption of stimulant beverages (> 5 coffee, tea, cola drinks daily).
  • Previous history of allergy, drug or idiosyncrasy.
  • Taking any medication in the 4 weeks preceding the trial, including non-prescription medicines and herbal remedies.
  • Positive serology for , C or .
  • History or clinical evidence of cardiovascular disease, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological, neurological or other chronic diseases.
  • Having had surgery during the previous 6 months.
  • Having donated blood in the month before the study began.
  • Smokers.
  • Positive pregnancy test at any monitoring during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Nifedipine oral solution

    Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose

    Drug: Nifedipine oral solution

  • Active comparator
    Nifedipine soft gelatine capsules

    Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose

    Drug: Nifedipine soft gelatine capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve (AUC 0-24h)

    Time frame: pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose

  2. Maximal plasmatic concentrations, Cmax

    Time frame: pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose

Secondary outcomes

  1. Time to maximal plasmatic concentrations, Tmax

    Time frame: pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose

07

Study locations

1 site
  • CIM Sant Pau
    Barcelona, 08025, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Feb 26, 2014
Start
Jan 2009
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Last update
Feb 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02071589
Lead sponsor
Reig Jofre Group
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Jan 2009
Primary completion
Mar 2009
Completion
Mar 2009
Last update
Feb 26, 2014

Study contacts

Rosa M Antonijoan, MD, PhD
principal investigator · CIM Sant Pau

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion